- Home
- Publications
- Publication Search
- Publication Details
Title
PD-1 inhibition in advanced myeloproliferative neoplasms
Authors
Keywords
-
Journal
Blood Advances
Volume 5, Issue 23, Pages 5086-5097
Publisher
American Society of Hematology
Online
2021-09-28
DOI
10.1182/bloodadvances.2021005491
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
- (2021) Jacob Handlos Grauslund et al. Frontiers in Oncology
- Survival following allogeneic transplant in patients with myelofibrosis
- (2020) Krisstina Gowin et al. Blood Advances
- Pembrolizumab for the treatment of Hodgkin Lymphoma
- (2020) Samer A. Al Hadidi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
- (2020) Muhammad Khan et al. Frontiers in Immunology
- Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma
- (2019) Ling Qian et al. PANCREATOLOGY
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms
- (2019) Jen-Chin Wang et al. LEUKEMIA RESEARCH
- Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms
- (2019) Cansu Cimen Bozkus et al. Cancer Discovery
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
- (2019) Imran G. House et al. CLINICAL CANCER RESEARCH
- Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
- (2019) Xianguang Bai et al. OncoTargets and Therapy
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
- (2018) Hans Michael Kvasnicka et al. Journal of Hematology & Oncology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
- (2018) Alessandro Prestipino et al. Science Translational Medicine
- Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands
- (2018) Mieke Metzemaekers et al. Frontiers in Immunology
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms
- (2016) M O Holmström et al. LEUKEMIA
- Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm
- (2016) Jen Chin Wang et al. LEUKEMIA RESEARCH
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity
- (2015) C. Cimen Bozkus et al. JOURNAL OF IMMUNOLOGY
- Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest
- (2015) Julie Mondet et al. MEDIATORS OF INFLAMMATION
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
- (2014) E. Rumi et al. BLOOD
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
- (2013) J. Mascarenhas et al. BLOOD
- Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity
- (2013) J. Huang et al. JOURNAL OF IMMUNOLOGY
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Increased prevalence of autoimmune phenomena in myelofibrosis: Relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns
- (2013) Wilma Barcellini et al. LEUKEMIA RESEARCH
- Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
- (2012) J. Mascarenhas et al. CURRENT MEDICINAL CHEMISTRY
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site
- (2011) Jessica M. Haverkamp et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now